title: [Experiment research on preventive effect of matrine on rat chronic nephrotoxicity induced by cyclosporin A].
abstract: OBJECTIVE
  To investigate the renal protective effect and possible mechanism of matrine on experimental cyclosporine A (CsA) induced chronic nephrotoxicity.
  
  
  METHODS
  56 male Sprague-Dawley rats were randomly divided into four groups: control group (olive oil 0. 2 mL/d), CsA group (CsA 20 mg/(kg x d)), Irbesartan group CCsA 20 mg/(kg x d) plus Irbesartan 10 mg/(kg x d)), matrine group CCsA 20 mg/(kg * d) plus matrine 100 mg/(kg x d)), and each group comprised fourteen rats. After treated with drugs, rats were sacrificed at the end of week 2 and 4. The body weight, 24-hours urine and blood sample were collected before rats sacrificed. The rat kidneys were taken and fixed in 10% neutral formaldehyde for HE staining. The osteopontin (OPN) and ectodermal dysplasia 1 (ED-1) were determined by immunohistochemical method. RESULTS Compared to control group, the 24-hour urine of rats, histological scores, the expression of OPN and the ED-1 positive cells number of CsA group were significantly increased, but Ccr was significantly lower (P<0. 05). Matrine could down-regulate OPN expression and decrease ED-1 positive cell infiltration in kidney, compared with CsA group (P <0. 05).
  
  
  CONCLUSIONS
  Matrine has a renal protective effect on chronic cyclosporine nephrotoxicity of rat model.
authors.affiliation: Department of Nephrology, West China Hospital, Sichuan University, Chengdu 610041, China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Jing
authors.forename: Ya-jun
authors.initials: YJ
authors.lastname: Bai
authors.forename: Yea
authors.initials: Y
authors.lastname: Tao
authors.forename: Ping
authors.initials: P
authors.lastname: Fu
authors.forename: Xin
authors.initials: X
authors.lastname: Wu
authors.forename: Dan-dan
authors.initials: DD
authors.lastname: Li
authors.forename: Qi-feng
authors.initials: QF
authors.lastname: Liu
mesh_terms: D000470:Alkaloids / Q000494:pharmacology*; D000818:Animals; D016572:Cyclosporine / Q000633:toxicity*; D015536:Down-Regulation; D053331:Ectodysplasins / Q000378:metabolism; D005786:Gene Expression Regulation / Q000187:drug effects; D007150:Immunohistochemistry; D008297:Male; D053495:Osteopontin / Q000378:metabolism; D011807:Quinolizines / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013154:Spleen / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D013997:Time Factors; D000093842:Matrines
chemical_list: D000470:Alkaloids; D053331:Ectodysplasins; D011807:Quinolizines; D053495:Osteopontin; D016572:Cyclosporine; D000093842:Matrines